Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...

The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

Thousands of women in the UK are planning to take legal action against Johnson & Johnson over alleged links between its baby ...

British women who claim talcum powder gave them ovarian cancer are planning to take Johnson & Johnson to court, in the first ...

Thousands of women could sue one of the world's biggest pharmaceutical companies after using its "cancer-causing" talcum ...

The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...

GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. Suitable for ...

Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...